All patients with HGA received prior radiation and temozolomide. Furthermore, prolonged stable disease (9 cycles) was observed in a patient with EGFRvIII mutant GBM. Expansion cohorts are in progress to optimize WSD0922-Fu dose and schedule for future phase 2 development.

6 months ago

Clinical • P1 data

EGFR mutation • EGFRvIII mutation

Tagrisso (osimertinib) • temozolomide • WSD0922

11ms

WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models. (PubMed, Neurooncol Adv)

The present preclinical study evaluated the novel EGFR inhibitor WSD-0922. We employed flank and orthotopic patient-derived xenograft models to characterize WSD-0922 and compare its efficacy to erlotinib, a potent EGFR inhibitor that failed to provide benefit for GBM patients...WSD-0922 treatment preferentially inhibited phosphorylation of several proteins, including those associated with EGFR inhibitor resistance and cell metabolism. WSD-0922 is a highly potent inhibitor of EGFR in GBM, and warrants further evaluation in clinical studies.

11 months ago

Preclinical • Journal

EGFR (Epidermal growth factor receptor)

erlotinib • WSD0922 • Undisclosed EGFR inhibitor

12ms

WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases (clinicaltrials.gov)

P1, N=51, Recruiting, Mayo Clinic | N=77 --> 51

12 months ago

Enrollment change

EGFR mutation • EGFR L858R • EGFR T790M • EGFR amplification • EGFR L861Q • EGFR C797S • EGFRvIII mutation • EGFR G719A • IDH wild-type

WSD0922